相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
Zhengbo Song et al.
BMC MEDICINE (2022)
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2022)
Targeting HER2-Mutant NSCLC - The Light Is On
Antonio Passaro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
Marcia R. Campbell et al.
CELL REPORTS (2022)
HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation
J. Lu et al.
ANNALS OF ONCOLOGY (2022)
Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
Veronique Dieras et al.
CANCER RESEARCH (2022)
Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial
Yasir Y. Elamin et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
Bob T. Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC
J. Strickler et al.
ANNALS OF ONCOLOGY (2022)
Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.
James J. Harding et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
Rupert Bartsch et al.
NATURE MEDICINE (2022)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian et al.
NATURE (2021)
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
Yoshiaki Nakamura et al.
NATURE MEDICINE (2021)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Martine Piccart et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Successful targeting of the NRG1 fusion reveals durable response to afatinib in lung adenocarcinoma: a case report
Xiaokang Wu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies
B. Li et al.
Journal of Thoracic Oncology (2021)
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena et al.
LANCET ONCOLOGY (2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
A. Bardia et al.
ANNALS OF ONCOLOGY (2021)
Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
J. Cortes et al.
ANNALS OF ONCOLOGY (2021)
RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.
Jiayu Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
Guy Heinrich Maria Jerusalem et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Milind Javle et al.
LANCET ONCOLOGY (2021)
HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors
Mark D. Pegram et al.
CLINICAL CANCER RESEARCH (2020)
Antibody-Drug Conjugates: A Comprehensive Review
Puregmaa Khongorzul et al.
MOLECULAR CANCER RESEARCH (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
F. Montemurro et al.
ANNALS OF ONCOLOGY (2020)
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin et al.
GYNECOLOGIC ONCOLOGY (2020)
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial
Yun Fan et al.
LUNG CANCER (2020)
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colrectal cancer: the phase II HERACLES-B trial
Andrea Sartore-Bianchi et al.
ESMO OPEN (2020)
A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy
Ziteng Li et al.
EBIOMEDICINE (2020)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bemstam et al.
LANCET ONCOLOGY (2019)
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma
Hideaki Takahashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys
Yoko Nagai et al.
XENOBIOTICA (2019)
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer
Alessandra Fabi et al.
BREAST (2018)
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T. Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Christoph Heining et al.
CANCER DISCOVERY (2018)
A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2018)
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
David M. Hyman et al.
NATURE (2018)
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Peter C. Thuss-Patience et al.
LANCET ONCOLOGY (2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and metaanalysis of randomised controlled trials
Zhi-Qiao Xu et al.
BMJ OPEN (2017)
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Alexander H. Staudacher et al.
BRITISH JOURNAL OF CANCER (2017)
Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors
Sherry Niessen et al.
CELL CHEMICAL BIOLOGY (2017)
Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors
Lars Dittus et al.
ACS CHEMICAL BIOLOGY (2017)
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
William Jacot et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
HER2 testing in gastric cancer: An update
Lucas Faria Abrahao-Machado et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers
Wenhsiang Wen et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum
A. Ruiz-Saenz et al.
ONCOGENE (2015)
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Shyam M. Kavuri et al.
CANCER DISCOVERY (2015)
The immune system and response to HER2-targeted treatment in breast cancer
Giampaolo Bianchini et al.
LANCET ONCOLOGY (2014)
Pharmacological targeting of the pseudokinase Her3
Ting Xie et al.
NATURE CHEMICAL BIOLOGY (2014)
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
Bryan R. Lannine et al.
NATURE CHEMICAL BIOLOGY (2014)
Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes
Saravana M. Dhanasekaran et al.
NATURE COMMUNICATIONS (2014)
CD74-NRG1 Fusions in Lung Adenocarcinoma
Lynnette Fernandez-Cuesta et al.
CANCER DISCOVERY (2014)
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation
David B. Vaught et al.
CANCER RESEARCH (2012)
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Maria E. Arcila et al.
CLINICAL CANCER RESEARCH (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
Britta Weigelt et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
Dhara N. Amin et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
Evelyn Yao et al.
CLINICAL CANCER RESEARCH (2009)
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2008)
Structure-based view of epidermal growth factor receptor regulation
Kathryn M. Ferguson
ANNUAL REVIEW OF BIOPHYSICS (2008)
A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy
Si Tuen Lee-Hoeflich et al.
CANCER RESEARCH (2008)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
The Other signaling of trastuzumab: Antibodies are immunocompetent drugs
Luca Gianni
JOURNAL OF CLINICAL ONCOLOGY (2008)
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes
Z. Cai et al.
ONCOGENE (2008)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
BC Pestalozzi et al.
ANNALS OF ONCOLOGY (2006)
Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas
JW Lee et al.
CLINICAL CANCER RESEARCH (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
WL Xia et al.
ONCOGENE (2005)
Phosphotyrosine interactome of the ErbB-receptor kinase family
Waltraud X. Schulze et al.
MOLECULAR SYSTEMS BIOLOGY (2005)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
U Gatzemeier et al.
ANNALS OF ONCOLOGY (2004)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis
SE Moody et al.
CANCER CELL (2002)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
WL Xia et al.
ONCOGENE (2002)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
